5-(docosane-1-sulfonyl)-1-phenyl-1H-tetrazole | 886455-41-0

• 分子结构分类: 有机化合物 - 有机杂环化合物 - 唑类
• 英文名称: 5-(docosane-1-sulfonyl)-1-phenyl-1H-tetrazole
• 英文别名: 5-(docosan-1-sulfonyl)-1-phenyl-1H-tetrazole；5-Docosylsulfonyl-1-phenyltetrazole
• CAS: 886455-41-0
• 化学式: C₂₉H₅₀N₄O₂S
• 分子量: 518.808
• InChiKey: POQBNTYRTVCOQK-UHFFFAOYSA-N

物化性质

• 熔点：
  56-59 °C
• 沸点：
  632.9±38.0 °C(Predicted)
• 密度：
  1.06±0.1 g/cm3(Predicted)

计算性质

• 辛醇/水分配系数(LogP)：
  11.8
• 重原子数：
  36
• 可旋转键数：
  23
• 环数：
  2.0
• sp3杂化的碳原子比例：
  0.76
• 拓扑面积：
  86.1
• 氢给体数：
  0
• 氢受体数：
  5

反应信息

• 作为反应物：
  描述：

  5-(docosane-1-sulfonyl)-1-phenyl-1H-tetrazole 在 氢氧化钾 、 lithium hexamethyldisilazane 作用下， 以 四氢呋喃 、 甲醇 、 正己烷 、 水 为溶剂， 反应 28.0h， 生成 methyl 2-((1R,2R)-1-(tert-butyldimethylsilyloxy)-10-hydroxydecyl)hexacosanoate
  参考文献：
  名称：

  An improved procedure for the preparation of the β-hydroxy-α-alkyl fatty acid fragment of mycolic acids

  摘要：

  An approach to a beta-hydroxy-alpha-alkyl fatty acid intermediate that can be applied in the synthesis of a range of mycolic acids is described. (c) 2006 Elsevier Ltd. All rights reserved.

  DOI：

  10.1016/j.tet.2006.01.070
• 作为产物：
  描述：

  1-溴二十二烷 在 ammonium molybdate tetrahydrate 、 双氧水 、 potassium carbonate 作用下， 以 四氢呋喃 、 水 、 丙酮 为溶剂， 生成 5-(docosane-1-sulfonyl)-1-phenyl-1H-tetrazole
  参考文献：
  名称：

  An improved procedure for the preparation of the β-hydroxy-α-alkyl fatty acid fragment of mycolic acids

  摘要：

  An approach to a beta-hydroxy-alpha-alkyl fatty acid intermediate that can be applied in the synthesis of a range of mycolic acids is described. (c) 2006 Elsevier Ltd. All rights reserved.

  DOI：

  10.1016/j.tet.2006.01.070

文献信息

• Compounds for Use in Therapy
  申请人：Baird Mark Stephen

  公开号：US20110150981A1

  公开（公告）日：2011-06-23

  A compound of formula (I) for use in the treatment of a disease of the immune system; wherein R is an optionally-substituted alkyl, alkenyl, alkynyl, aryl, arylalkyl or alkylaryl moiety having from 1 to 50 carbon atoms; R 1 is an optionally-substituted alkyl, alkenyl, alkynyl, aryl, arylalkyl or alkylaryl moiety having from 1 to 40 carbon atoms; each of R 2 , Wand R 4 is independently selected from an optionally-substituted alkylene, alkenylene, alkynylene, arylene, arylalkylene or alkylarylene moiety having from 1 to 40 carbon atoms; each of X, Y and Z is independently selected from an optionally-substituted alkylene, alkenylene, alkenylene, arylene, alkylarylene, cycloalkylene, ketone, ester, amide, imide, imine, thioether, ether, thioester and thioketone; and P is selected from hydrogen, an alkyl group, a sugar residue, or a metal, phosphonium or ammonium species; wherein at least one of X, Y and Z includes a moiety selected from cyclopropyl, C=A, C-AH and C-OR 5 ; wherein R 5 is alkyl or haloalkyl, and A is O, S or Me, wherein R 6 may be H or 20 alkyl.

  化合物式（I）的化合物用于治疗免疫系统疾病；其中R是具有1至50个碳原子的可选取代的烷基，烯基，炔基，芳基，芳基烷基或烷基芳基基团；R1是具有1至40个碳原子的可选取代的烷基，烯基，炔基，芳基，芳基烷基或烷基芳基基团；R2，W和R4中的每一个都独立地选择自具有1至40个碳原子的可选取代的烷基，烯基，炔基，芳基，芳基烷基或烷基芳基基团的取代的烷基，烯基，炔基，芳基，芳基烷基或烷基芳基基团；X，Y和Z中的每一个都独立地选择自可选取代的烷基，烯基，烯基，芳基，烷基芳基，环烷基，酮，酯，酰胺，亚酰胺，亚胺，硫醚，醚，硫酯和硫酮的基团；P从氢，烷基，糖残基或金属，膦，铵或铵物种中选择；其中X，Y和Z中至少有一个包括从环丙基，C = A，C-AH和C-OR5中选择的基团；其中R5是烷基或卤代烷基，A是O，S或Me，R6可能是H或20烷基。
• Adjuvants for Use in Vaccination
  申请人：Baird Mark Stephen

  公开号：US20110142916A1

  公开（公告）日：2011-06-16

  A compound of formula (I) for use as an adjuvant in vaccination; wherein R is an optionally-substituted alkyl, alkenyl, alkynyl, aryl, arylalkyl or alkylaryl moiety having from 1 to 50 carbon atoms; R 1 is an optionally-substituted alkyl, alkenyl, alkynyl, aryl, arylalkyl or alkylaryl moiety having from 1 to 40 carbon atoms; each of R 2 , R 3 and R 4 is independently selected from an optionally-substituted alkylene, alkenylene, alkynylene, arylene, arylalkylene or alkylarylene moiety having from 1 to 40 carbon atoms; each of X, Y and Z is independently selected from an optionally-substituted alkylene, alkenylene, alkynylene, arylene, alkylarylene or cycloalkylene, ketone, ester, amide, imide, imine, thioether, ether, thioester, thioketone; and P is selected from hydrogen, an alkyl group, a sugar residue, or a metal, phosphonium or ammonium species; wherein at least one of X, Y and Z includes a moiety selected from cyclopropyl, C=A, C-AH and C—OR 5 ; wherein R 5 is alkyl or haloalkyl, and A is S, O or NR 6 , wherein R 6 maybe H or 20 alkyl.

  化合物式（I）的复合物用作疫苗佐剂；其中R是具有1至50个碳原子的可选取代的烷基，烯基，炔基，芳基，芳基烷基或烷基芳基基团; R1是具有1至40个碳原子的可选取代的烷基，烯基，炔基，芳基，芳基烷基或烷基芳基基团; R2，R3和R4中的每一个都是独立选择的，具有1至40个碳原子的可选取代的烷基，烯基，炔基，芳基，芳基烷基或烷基芳基基团; X，Y和Z中的每一个都是独立选择的，具有1至40个碳原子的可选取代的烷基，烯基，炔基，芳基，烷基芳基或环烷基，酮，酯，酰胺，亚酰胺，亚胺，硫醚，醚，硫酯，硫酮; P是氢，烷基，糖残基或金属，膦或铵物种中的一种；其中X，Y和Z中至少一个包括从环丙基，C=A，C-AH和C—OR5中选择的基团; 其中R5是烷基或卤代烷基，A是S，O或NR6，其中R6可以是H或20烷基。
• Adjuvants for use in vaccination
  申请人：Bangor University

  公开号：EP2620158A1

  公开（公告）日：2013-07-31

  A compound of formula IId is described for use as an adjuvant in vaccination; wherein R6 is hydrogen or C1 to C4 alkyl, R7 is hydrogen or C1 to C4 alkyl, p is from 16 to 30, q is from 8 to 24, r is from 12 to 28 and s is from 12 to 28.

  描述了式 IId 的化合物 其中 R6 是氢或 C1 至 C4 烷基，R7 是氢或 C1 至 C4 烷基，p 是 16 至 30，q 是 8 至 24，r 是 12 至 28，s 是 12 至 28。
• The synthesis of single enantiomers of mycobacterial ketomycolic acids containing cis-cyclopropanes
  作者：Gani Koza、Cornelia Theunissen、Juma'a R. Al Dulayymi、Mark S. Baird

  DOI：10.1016/j.tet.2009.09.099

  日期：2009.12

  We report the syntheses of a single enantiomer of an unprotected ketomycolic acids containing a cis-cyclopropane and of related hydroxy-mycolic acids. (C) 2009 Elsevier Ltd. All rights reserved.
• The first syntheses of single enantiomers of the major methoxymycolic acid of Mycobacterium tuberculosis
  作者：Juma'a R. Al Dulayymi、Mark S. Baird、Evan Roberts、Madrey Deysel、Jan Verschoor

  DOI：10.1016/j.tet.2007.01.007

  日期：2007.3

  The synthesis of three stereoisomers of a major homologue of the methoxymycolic acids present in Mycobacterium tuberculosis is described. (c) 2007 Elsevier Ltd. All rights reserved.